Treatment with irbesartan, amlodipine, or placebo led to the same composite cardiovascular event rate (cardiovascular death,
myocardial infarction, congestive heart failure, strokes, and coronary revascularization) in patients with type 2 diabetes
and overt nephropathy who also received conventional antihypertensive therapy.